CO4970824A1 - METHOD TO REDUCE ANXIES OF CONSUMPTION IN MAMMALS - Google Patents

METHOD TO REDUCE ANXIES OF CONSUMPTION IN MAMMALS

Info

Publication number
CO4970824A1
CO4970824A1 CO98062495A CO98062495A CO4970824A1 CO 4970824 A1 CO4970824 A1 CO 4970824A1 CO 98062495 A CO98062495 A CO 98062495A CO 98062495 A CO98062495 A CO 98062495A CO 4970824 A1 CO4970824 A1 CO 4970824A1
Authority
CO
Colombia
Prior art keywords
anxies
mammals
consumption
reduce
mammal
Prior art date
Application number
CO98062495A
Other languages
Spanish (es)
Inventor
Vicki Coffin
Paul W Glue
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO4970824A1 publication Critical patent/CO4970824A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se describen un método para reducir en un mamífero las ansiasde consumo de alimentos o de una sustancia adictiva. El método consiste en administrar al mamífero una cantidad efectiva de un antagonista de D1 /D5 o un agonista parcial de D1 /D5 solo o en combinación con otros compuestos para el SNC especificados.A method of reducing cravings for food or an addictive substance is described in a mammal. The method is to administer to the mammal an effective amount of a D1 / D5 antagonist or a D1 / D5 partial agonist alone or in combination with other specified CNS compounds.

CO98062495A 1997-10-28 1998-10-26 METHOD TO REDUCE ANXIES OF CONSUMPTION IN MAMMALS CO4970824A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95921397A 1997-10-28 1997-10-28

Publications (1)

Publication Number Publication Date
CO4970824A1 true CO4970824A1 (en) 2000-11-07

Family

ID=25501785

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98062495A CO4970824A1 (en) 1997-10-28 1998-10-26 METHOD TO REDUCE ANXIES OF CONSUMPTION IN MAMMALS

Country Status (16)

Country Link
EP (1) EP1043980A2 (en)
JP (1) JP2001520989A (en)
KR (1) KR20010031470A (en)
CN (1) CN1283116A (en)
AR (1) AR015984A1 (en)
AU (1) AU1110099A (en)
BR (1) BR9814830A (en)
CA (1) CA2308453A1 (en)
CO (1) CO4970824A1 (en)
HU (1) HUP0100115A2 (en)
IL (1) IL135659A0 (en)
NO (1) NO20002149L (en)
PE (1) PE122299A1 (en)
SK (1) SK5812000A3 (en)
WO (1) WO1999021540A2 (en)
ZA (1) ZA989786B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US6395783B1 (en) 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
ATE427745T1 (en) 2001-11-05 2009-04-15 Krele Pharmaceuticals Llc COMPOSITIONS AND METHODS FOR INCREASE COMPLIANCE WITH THERAPIES USING ALDEHYDE DEHYDROGENASE INHIBITORS AND FOR TREATING ALCOHOLSM
DK2611440T3 (en) 2010-09-01 2017-05-15 Tonix Pharmaceuticals Inc Treatment for cocaine addiction
HUE058696T2 (en) 2012-07-12 2022-09-28 Emalex Biosciences Inc Fused benzazepines for treatment of tourette's syndrome
HUE049848T2 (en) 2013-10-18 2020-11-30 Emalex Biosciences Inc Fused benzazepines for treatment of stuttering
CN110327350B (en) * 2019-07-11 2021-02-23 温州医科大学 Application of dopamine D1 receptor antagonist SCH39166 in preparation of drugs for treating pathological angiogenesis of eyes
CN110833621A (en) * 2019-12-06 2020-02-25 中国医科大学 Application of dopamine receptor 1 antagonist in preparation of drug for treating mouse schizophrenia caused by ketamine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
WO1997046239A1 (en) * 1996-06-06 1997-12-11 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists

Also Published As

Publication number Publication date
NO20002149L (en) 2000-06-26
PE122299A1 (en) 1999-12-04
NO20002149D0 (en) 2000-04-27
CA2308453A1 (en) 1999-05-06
KR20010031470A (en) 2001-04-16
ZA989786B (en) 1999-04-28
CN1283116A (en) 2001-02-07
BR9814830A (en) 2000-10-03
SK5812000A3 (en) 2000-12-11
WO1999021540A3 (en) 1999-09-02
WO1999021540B1 (en) 1999-10-28
AU1110099A (en) 1999-05-17
JP2001520989A (en) 2001-11-06
EP1043980A2 (en) 2000-10-18
WO1999021540A2 (en) 1999-05-06
IL135659A0 (en) 2001-05-20
HUP0100115A2 (en) 2001-06-28
AR015984A1 (en) 2001-05-30

Similar Documents

Publication Publication Date Title
CO4970824A1 (en) METHOD TO REDUCE ANXIES OF CONSUMPTION IN MAMMALS
EA200300337A1 (en) POLYARILKARBOXAMIDES APPLICABLE AS AN AGENTS REDUCING THE CONTENT OF LIPIDS
UA41316C2 (en) tricyclic derivatives of pyrrole and pharmaceutical agent
HUP0100065A2 (en) Novel suppository comprising an acid-sensitive active compound
DE3872666D1 (en) LUBRICANT COMPOSITION TO REDUCE FUEL CONSUMPTION.
DE69529998D1 (en) GLP-1 COMPOSITIONS WITH EXTENDED EFFECT
ES2118393T3 (en) CHEMYLUMINISCENT COASTER.
ID22812A (en) COMPOUND 2-IMIDAZOLINYLAMINOINDOL USING ALFA-2 ADRENOSEPTOR AGONISTS
DE3562267D1 (en) Phenanthridinium ester as a labelling compound in luminometric immunoassay
SV2002000244A (en) METHODS AND COMPOUNDS TO INHIBIT MRP1 REF.X-13353
ES2148593T3 (en) NOVELTY TRIENOIC RETINOID COMPOUNDS AND METHODS.
ATE247617T1 (en) ANTI-INFLAMMATORY ANTIBACTERIAL BENZYLPHENOL COMPOUNDS
EP1084098A4 (en) Inhibitors of the anandamide transporter as analgesic agents
DE3872333D1 (en) DOXAZOSIN AS AN ANTIATHEROSCLEROTIC.
ATE297402T1 (en) PHOSPHOLIPIDS WITH UNSATURATED ALKYL AND ACYL CHAINS
ES530943A0 (en) PROCEDURE TO DETERMINE THE CONTENT OF A FUEL ROD.
AR017216A1 (en) METHOD FOR REGULATING PHAGOCITOSIS OF CELLS OF MAMMALS.
EA199800200A1 (en) Prolylendopeptidase inhibitors
IS4673A (en) Light phenyl pyrimidine derivative as an analgesic agent
IL88366A0 (en) Tert-butylphenyl compounds useful as anti-inflammatory agents
ECSP982714A (en) METHOD TO REDUCE CONSUMER ANXIAS IN MAMMALS (CASE CN0792K)
DE3873562T2 (en) BETA ALKYL MELATONINE.
ATE34661T1 (en) LIPID LEVEL REDUCING COMPOUNDS.
ATE231510T1 (en) PENAMSULFONES AS BETA-LACTAMASE INHIBITORS
DK1095275T3 (en) Endogenous, constitutively activated G protein-coupled orphan receptors